Article Text

Download PDFPDF

6ER-002 Efficacy of a fixed-ratio combination of insulin degludec and liraglutide in the treatment of type 2 diabetes mellitus
  1. V Ožana1,
  2. M Frydrych2
  1. 1Hospital with Polyclinic Karvina-Raj- Orlova City Branch, Pharmacy, Orlova, Czech Republic
  2. 2University of Veterinary and Pharmaceutical Sciences Brno, Department of Human Pharmacology and Toxicology- Faculty of Pharmacy, Brno, Czech Republic


Background Based on the current recommendations, a fixed-ratio combination of insulin degludec and GLP-1 agonist liraglutide (IDegLira) is considered to be an equivalent alternative to an intensified insulin regimen for type 2 diabetes mellitus (T2DM). As a once-daily injection with effects on both fasting and postprandial hyperglycaemia, IDegLira provides, according to several studies, optimal glycemic and metabolic control.

Purpose To determine the effectiveness of IDegLira in the reduction of glycemic parameters, bodyweight and lipid profile parameters in patients with a diagnosis of T2DM.

Material and methods A retrospective observational study was conducted in a diabetic clinic of a regional hospital. Clinical data and demographic characteristics were obtained from computerised medical records and processed by Microsoft Excel. Overall, 52 participants were selected with T2DM who were treated with IDegLira in addition to oral antidiabetic drugs for at least 52 weeks between October 2016 and January 2018. The effectiveness of IDegLira was analysed through measuring glycated haemoglobin (HbA1c), fasting plasma glucose (FPG), and bodyweight and lipid profile parameters at the beginning of the treatment and at week 52.

Results Fifty-two patients were included in total. Mean age: 61.2 years (38–78): 25 females and 27 males. Average duration of diabetes: 8.5 years (2.8–19.9). After 52 weeks the mean HbA1c decreased from a baseline of 72.3±1.4 mmol/mol by 7.3±1.8 mmol/mol (p<0.001). The mean FPG was reduced from a baseline of 9.6±0.4 mmol/L by 1.5±0.4 mmol/L (p<0.001). Average weight loss was −0.45±0.32 kg (p=0.161). Mean changes in lipid profile parameters such as total cholesterol, LDL-cholesterol and triglycerides were statistically insignificant except for HDL-cholesterol, which increased from a baseline of 1.06±0.05 mmol/L by 0.04±0.02 mmol/L (p=0.014). Compared to the data from the DUAL Clinical Trial Programme, the reduction in glycemic parameters attained in this study was less pronounced presumably due to the smaller number of participants and different baseline characteristics.

Conclusion The conducted study confirms that the positive impact of IDegLira on glycemic compensation in patients with T2DM as a statistically significant decrease in parameters of glycemic control was achieved. On the contrary, the weight reduction and almost all the changes in plasma lipid concentrations were insignificant.

References and/or acknowledgements

No conflict of interest.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.